Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Arecor Therapeutics PLC ( (GB:AREC) ).
Arecor Therapeutics has sharpened its strategy around two core franchises, diabetes and oral peptide delivery, both in high-growth multi-billion-dollar segments, while advancing its lead insulin asset AT278 and an oral GLP-1 programme. The company reported 2025 revenues of £3.1 million, down due to the closure of Tetris Pharma, but ended the year with £6.1 million in cash, exceeding expectations and underpinning continued R&D investment.
The group made notable progress with AT278 in 2025, securing positive FDA feedback on a first-of-its-kind Phase 2 trial design that will test the ultra-concentrated insulin in combination with automated insulin delivery systems. Arecor also entered a co-development deal with Sequel Med Tech to pair AT278 with Sequel’s US-launched twiist AID pump and is negotiating a broader partnership, while advancing non-clinical studies and new IP filings for its oral peptide platform aimed at improving semaglutide bioavailability and enabling wider oral peptide applications.
The most recent analyst rating on (GB:AREC) stock is a Hold with a £84.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.
Spark’s Take on GB:AREC Stock
According to Spark, TipRanks’ AI Analyst, GB:AREC is a Neutral.
Arecor Therapeutics’ score is driven by positive corporate events, including strategic partnerships and IP expansion, which bolster its market position. However, financial performance challenges, such as ongoing losses and cash flow issues, weigh heavily on the overall score. Technical analysis and valuation present a neutral outlook, reflecting the typical risks and opportunities in the biotech sector.
To see Spark’s full report on GB:AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a Cambridge, UK-based clinical-stage biopharmaceutical company focused on drug development and enhanced delivery for diabetes and other cardiometabolic diseases. Leveraging its Arestat platform, it is developing AT278, an ultra-concentrated, ultra-rapid-acting insulin, and an oral peptide delivery platform targeting obesity and diabetes markets.
Average Trading Volume: 39,378
Technical Sentiment Signal: Buy
Current Market Cap: £29.26M
See more insights into AREC stock on TipRanks’ Stock Analysis page.